Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283 Compared With mRNA-1273 in Participants Aged ≥12 Years for the Prevention of COVID-19

NCT05815498 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05815498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05815498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283 Compared With mRNA-1273 in Participants Aged ≥12 Years for the Prevention of COVID-19
Lead sponsor
ModernaTX, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 28, 2023
Completion date
April 12, 2025
Enrollment
13,553 (actual)
Sites
230

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19